Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
GSK, a British pharmaceutical and biotech firm that was formerly known as Glaxo Smith Kline plc, announced that it had hired Julie Brown to be its new chief financial officer. The company said on Monday, Sept. 26, that the executive would formally join GSK next week.
According to Sky News, the move to recruit Brown is a strategy to form an all-female team of executives. It was reported that the newly-recruited CFO was poached by GSK from the Burberry Group PLC fashion company.
Brown will be replacing Iain Mackay, who is set to retire. He has been serving as GSK’s finance chief since 2019. The formation of an all-female team is very rare in the business, but the company is aiming for this with the recruitment of Brown.
Reuters reported that Brown is set to step down in April 2023 from Burberry after serving for more than five years as its CFO. She is a 60-year-old British woman who started working at the said fashion house in 2017. Prior to this, she worked at Smith & Nephew's medical device products manufacturing firm.
She also held an executive job role in AstraZeneca as interim group CFO and was appointed to senior roles at some of GSK’s rival companies. In addition, she was a non-executive director of Roche Holding Swiss healthcare group, but she is likely to step down after accepting the CFO role at GSK.
“I want to thank Iain for all he’s done for GSK, and for his leadership and support to our people. He has played a very significant role to help deliver the reshaping of GSK and to improve our operating and financial performance,” GSK’s chief executive officer, Emma Walmsley, said in a press release. “I am absolutely delighted that Julie will be joining the leadership team as his successor. Julie is a highly experienced CFO with a tremendous understanding of the biopharma sector.”
The CEO added, “We also share a strong passion for people development, diversity, inclusion and sustainability. I am looking forward to working together to deliver progress for patients, shareholders and our people.”
